HIV daily pill regimen could be replaced with just as effective monthly injectable treatment

The latest early trial data suggests that current daily HIV pill regimens could potentially be replaced with injections that slowly release medication for the virus over time. This new method has proven to be as successful as current treatment plans and could provide the same benefits in just six injections annually. Antiretroviral treatment suppresses the

Continue Reading

Study conducted by ViiV Healthcare shows effectiveness of two drug HIV treatment

The pharmaceutical company recently unveiled late stage data that shows their experimental two-drug regimen of its dolutegravir and Janssen Science’s rilpivirine was comparable in efficacy to three- or four-drug antiretroviral regimens in virologically suppressed patients. The dolutegravir/rilpivirine combination treatment achieved non-inferior viral suppression at 48 weeks compared with a three- or four-drug regimen in both

Continue Reading

ViiV’s HIV Drug, Tivicay, Launched in the UK

diagnosis Tivicay, Launched in the UK” src=”http://i57.tinypic.com/2re6t69.jpg” width=”164″ height=”147″ />HIV patients in the UK will from this week have another treatment option after ViiV Healthcare announced the launch of their once-daily drug, Tivicay (dolutegravir). The integrase inhibitor was approved in Europe last month for HIV-1 in a broad patient population of treatment-naive and treatment-experienced adults

Continue Reading